Oral Delivery Strategies for Biological Drugs
Small Methods · 2025-07 · 9 (7)
DOI: 10.1002/smtd.202401355 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Methods, online erschienen am 21.03.2025. Verfasst von Huiling Zeng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China. Hauptthemen laut MEDLINE: Drug Delivery Systems, Biological Products. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 325 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine.
Abstract (Originalsprache)
Biologics have low toxicity and are highly specific and biocompatible, offering advantages over small‐molecule drugs. The administration of biologics in oral form provides a significant benefit in improving patient compliance. However, oral administration faces the challenge of a harsh gastrointestinal environment, including low pH, enzyme degradation, and poor intestinal epithelium permeability, which limits the bioavailability of biologics. As a result, the administration of biologics remains primarily in the parenteral form. This review introduces the physiological barriers encountered by oral biologics delivery, describes the oral biologics currently on the market or under clinical trials, as well as oral biologics‐based technologies, and discusses the recent progress on novel oral delivery technologies such as nanoparticle‐delivery systems, ionic liquids, and microneedles. Specifically, colon‐targeted approaches for oral biologics delivery are also explored, as the colon could be a more optimal absorption site due to having less diverse proteolytic enzymes and relatively limited digestibility compared to the upper gastrointestinal tract (GIT). Lastly, the future research directions for oral biologics are highlighted and it is concluded that with an in‐depth study of biological drugs and advancement in delivery methods, oral biologics can pioneer new opportunities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.
- School of Pharmacy, China Pharmaceutical University, Nanjing, 210000, China.
- School of Science, China Pharmaceutical University, Nanjing, 210000, China.
- School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, Guangdong, 511436, China.
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
ORCID-Profile: Wei Tao
Förderung
- National Natural Science Foundation of China
- Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine
Zitieren
APA
Zeng, H., Ma, M., Peng, X., Xie, Y., Xie, A., Deng, B., Ouyang, J., Tao, W., Yang, P., & He, W. (2025). Oral Delivery Strategies for Biological Drugs. Small Methods, 9(7). https://doi.org/10.1002/smtd.202401355
Vancouver
Zeng H, Ma M, Peng X, Xie Y, Xie A, Deng B, et al. Oral Delivery Strategies for Biological Drugs. Small Methods. 2025;9(7). doi:10.1002/smtd.202401355
BibTeX
@article{Zeng2025,
author = {Zeng, Huiling and Ma, Mingyang and Peng, Xiuju and Xie, Yangyang and Xie, Angel and Deng, Bo and Ouyang, Jiang and Tao, Wei and Yang, Pei and He, Wei},
title = {Oral Delivery Strategies for Biological Drugs},
journal = {Small Methods},
year = {2025},
volume = {9},
number = {7},
doi = {10.1002/smtd.202401355}
}
EUVIMED